The US Federal Trade Commission officially instructed Illumina to divest Grail, claiming that the merger may stifle competition and patient access in the cancer diagnostics market, but the company has not given up on the deal yet.
The merger deal was first announced in September 2020 and, despite immediate opposition from regulators, Illumina declared that the deal had completed with a value of approximately $8bn in August 2021
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?